TABLE 1.
Antiresorptive agents approved in the United States, in order of year first marketed.
| Indications drugs | Osteoporosis in postmenopausal women | Osteoporosis in men | Glucocorticoid-induced osteoporosis | Paget” s disease of bone | Multiple myeloma and bone metastasis from solid tumors | Hypercalcemia of malignancy | Giant cell tumor of bone | Brand name | Year of first marketed |
|---|---|---|---|---|---|---|---|---|---|
| Etidronate | N | N | N | Y | N | N | N | Didronel | 09/01/1977 |
| Pamidronate | N | N | N | Y | Y | Y | N | Aredia | 10/31/1991 |
| Alendronate | Y | Y | Y | Y | N | N | N | Fosamax | 09/29/1995 |
| Risedronate | Y | Y | Y | Y | N | N | N | Actonel | 03/27/1998 |
| Zoledronic Acid | Y | Y | Y | Y | Y | Y | N | Zometa | 8/20/2001 |
| Ibandronate | Y | N | N | N | N | N | N | Boniva | 05/16/2003 |
| Denosumab | Y | Y | Y | Y | Y | Y | Y | Xgeva | 06/01/2010 |
| Romosozumab | Y | N | N | N | N | N | N | Evenity | 04/09/2019 |